Progenics Pharmaceuticals (NASDAQ:PGNX) Receives Daily News Impact Score of 0.12

News headlines about Progenics Pharmaceuticals (NASDAQ:PGNX) have trended somewhat positive this week, Accern reports. The research group identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Progenics Pharmaceuticals earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 44 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the media stories that may have impacted Accern’s scoring:

Progenics Pharmaceuticals (NASDAQ:PGNX) opened at 6.21 on Friday. The stock has a market capitalization of $436.10 million, a P/E ratio of 64.02 and a beta of 3.36. The company’s 50-day moving average price is $6.86 and its 200 day moving average price is $8.40. Progenics Pharmaceuticals has a 52-week low of $4.84 and a 52-week high of $11.72.

Progenics Pharmaceuticals (NASDAQ:PGNX) last announced its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by $0.07. Progenics Pharmaceuticals had a net margin of 10.24% and a return on equity of 7.50%. The company had revenue of $2.40 million during the quarter, compared to analysts’ expectations of $4.50 million. During the same period last year, the firm earned ($0.18) earnings per share. Progenics Pharmaceuticals’s revenue was down 4.0% on a year-over-year basis. On average, equities research analysts predict that Progenics Pharmaceuticals will post ($0.84) earnings per share for the current fiscal year.

Several brokerages have recently issued reports on PGNX. Jefferies Group LLC increased their target price on Progenics Pharmaceuticals from $13.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, April 4th. Zacks Investment Research raised Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, June 6th. Cantor Fitzgerald began coverage on Progenics Pharmaceuticals in a report on Wednesday, July 12th. They issued an “overweight” rating and a $15.00 target price for the company. BidaskClub lowered Progenics Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 11th. Finally, Needham & Company LLC reissued a “strong-buy” rating and issued a $14.00 target price on shares of Progenics Pharmaceuticals in a report on Sunday, April 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $12.33.

TRADEMARK VIOLATION WARNING: This piece was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at

About Progenics Pharmaceuticals

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.

Insider Buying and Selling by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Receive News & Ratings for Progenics Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply